Table 14.27.1.

Generation of Lung Orthotopic Tumors Using NSCLC Cell Lines

Cell line	Lung disease	Cell numbera	Days to morbidityb	Commercial source	References
NCI-H1299c	Carcinoma	0.1–1 × 106	32–90	ATCC	Onn et al. (2003); V.J. and A.P.F. (unpub. observ.)
A549c	Carcinoma	1–3 × 106	50–64	ATCC	Mordant et al. (2011); Madero-Visbal et al. (2012); V.J. and A.P.F. (unpub. observ.)
NCI-H358c	Bronchioloalveolar carcinoma	0.5–1 × 106	42–80	ATCC	Onn et al. (2003)
NCI-H1703	Adenocarcinoma	1 × 106	<90	ATCC	V.J. and A.P.F. (unpub. observ.)
NCI-H441	Adenocarcinoma	1 × 106	55	ATCC	Takahashi et al. (2012)
NCI-H460	Large cell carcinoma	0.5–1 × 106	19–90	ATCC	Jin (2004); Takahashi et al. (2012)
NCI-H226	Squamous cell carcinoma	1.5–2 × 106	63–120	ATCC	Onn et al. (2003)
CMT 167c	Carcinoma from mouse	1 × 103	35	Sigma	Justilien et al. (2012)
Lewis lung carcinomac	Carcinoma from mouse	1 × 103	21	Life Technologies (Invitrogen)	Doki et al. (1999); V.J. and A.P.F. (unpub. observ.)

^aNumber of cells implanted to produce reproducible tumors.

^bTime in days after injection to mice showing signs of morbidity.

^cMetastasis to ipsilateral and contralateral lobes of the lung and the mediastinal lymph nodes.